Literature DB >> 6509359

Design of phase I and II clinical trials in cancer: a statistician's view.

N L Geller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6509359     DOI： 10.3109/07357908409048522

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  9 in total

1.  Does palliative chemotherapy palliate?

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

2.  Partial responses to antineoplastic drug therapy: what do they mean?

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 3.  How to design a phase I trial of an anticancer botanical.

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2006

4.  Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.

Authors:  N R Cutler; J J Sramek
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Phase 1 trials of intensive antineoplastic therapy: a need for a critical reassessment of who should be treated.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

6.  Stochastic Approximation and Modern Model-based Designs for Dose-Finding Clinical Trials.

Authors:  Ying Kuen Cheung
Journal:  Stat Sci       Date:  2010-05       Impact factor: 2.901

Review 7.  Recommendations for planning pilot studies in clinical and translational research.

Authors:  Charity G Moore; Rickey E Carter; Paul J Nietert; Paul W Stewart
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

8.  The changing face of phase 1 cancer clinical trials: new challenges in study requirements.

Authors:  Barbara S Craft; Razelle Kurzrock; Xiudong Lei; Roy Herbst; Scott Lippman; Siqing Fu; Daniel D Karp
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

Review 9.  Principles of dose finding studies in cancer: a comparison of trial designs.

Authors:  Thomas Jaki; Sally Clive; Christopher J Weir
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-09       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.